

S/N 09/047,652

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Vassilios Papadopoulos et al. Examiner: Minh-Tam Davis  
Serial No.: 09/047,652 Group Art Unit: 1642  
Filed: March 25, 1998 Docket: 1941.016US1  
Title: PERIPHERAL-TYPE BENZODIAZEPINE RECEPTOR: A TOOL FOR  
DETECTION, DIAGNOSIS, PROGNOSIS, AND TREATMENT OF CANCER


---

COMMUNICATION CONCERNING RELATED APPLICATION(S)

Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Applicants would like to bring to the Examiner's attention the following related application(s) in the above-identified patent application:

<u>Serial/Patent No.</u>	<u>Filing Date/Issue Date</u>	<u>Attorney Docket</u>	<u>Title</u>
09/646,932	September 25, 2000	1941.016US2	Peripheral-Type Benzodiazepine Receptor: A Tool for Detection, Diagnosis, Prognosis, and Treatment of Cancer
09/762,594	June 22, 2001	1941.015US1	DNA ENCODING PERIPHERAL-TYPE BENZODIAZEPINE RECEPTOR ASSOCIATED PROTEIN 7, AND APPLICATIONS OR METHODS OF USE
11/331,940	January 13, 2006	1941.015US2	PERIPHERAL-TYPE BENZODIAZEPINE RECEPTOR ASSOCIATED PROTEINS, CLONING, EXPRESSION AND METHODS OF USE



COMMUNICATION CONCERNING RELATED APPLICATIONS

Serial Number: 09/047,652

Filing Date: March 25, 1998

Title: PERIPHERAL-TYPE BENZODIAZEPINE RECEPTOR: A TOOL FOR DETECTION, DIAGNOSIS, PROGNOSIS, AND TREATMENT OF CANCER

Page 2

Dkt: 1941.016US1

Continuations and divisionals may be later filed on the cases listed above, or cited to the Examiner in any previous Communication Concerning Related Applications. Applicants request that the Examiner review all continuations and divisionals of the above-listed or previously-cited patent applications before allowing the claims of the present patent application.

Respectfully submitted,

VASSILIOS PAPADOPOULOS ET AL.

By Applicants' Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

P.O. Box 2938

Minneapolis, MN 55402

(612) 373-6959

Date

February 23, 2006

By

Janet E. Embretson


Reg. No. 39,665

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 23 day of February, 2006.

John D. Gustafson, Esq.

Name

Signature



S/09/047,652

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant:	Vassilios Papadopoulos et al.	Examiner:	Minh-Tam Davis
Serial No.:	09/047,652	Group Art Unit:	1642
Filed:	March 25, 1998	Docket:	1941.016US1
Title:	Peripheral-Type Benzodiazepine Receptor: A Tool for Detection, Diagnosis, Prognosis, and Treatment of Cancer		


---

**INFORMATION DISCLOSURE STATEMENT**

Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. §1.97(b), it is believed that no fee or statement is required with the Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 19-0743 in order to have this Information Disclosure Statement considered.



INFORMATION DISCLOSURE STATEMENT

Serial No : 09/047,652

Filing Date: March 25, 1998

Title: Peripheral-Type Benzodiazepine Receptor: A Tool for Detection, Diagnosis, Prognosis, and Treatment of Cancer

Page 2

Dkt: 1941.016US1

Pursuant to 37 C.F.R. 1.98(a)(2), Applicant believes that copies of cited U.S. Patents and Published Applications are no longer required to be provided to the Office. Notification of this change was provided in the United States Patent and Trademark Office OG Notices dated October 12, 2004. Thus, Applicant has not included copies of any US Patents or Published Applications cited with this submission. Should the Office require copies to be provided, Applicant respectfully requests that notice of such requirement be directed to Applicant's below-signed representative. Applicant acknowledges the requirement to submit copies of foreign patent documents and non-patent literature in accordance with 37 C.F.R. 1.98(a)(2).

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

VASSILIOS PAPADOPOULOS ET AL.


By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.  
P.O. Box 2938  
Minneapolis, MN 55402  
(612) 373-6959

Date

February 23, 2006

By

  
Janet E. Embretson  
Reg. No. 39,665


CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 23 day of February, 2006.

Name

John D. Gustafson, Weathall

Signature





Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)	<i>Complete if Known</i>	
	<b>Application Number</b>	09/047,652
	<b>Filing Date</b>	March 25, 1998
	<b>First Named Inventor</b>	Papadopoulos, Vassilios
	<b>Group Art Unit</b>	1642
	<b>Examiner Name</b>	Davis, Minh-Tam
Sheet 1 of 3		Attorney Docket No: 1941.016US1

US PATENT DOCUMENTS				
Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
	US-2003/0157095A1	08/21/2003	Papadopoulos, V.	03/25/1998
	US-5,350,836	09/27/1994	Kopchick, J. J., et al.	05/04/1992
	US-5,948,676	09/07/1999	Chang, Y. , et al.	10/10/1996


FOREIGN PATENT DOCUMENTS				
Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T <sup>2</sup>
	WO-0001821A2	01/13/2000	Lal, P. , et al.	
	WO-0009549A2	02/24/2000	Papadopoulos, V.	
	WO-9949316A2	09/30/1999	Papadopoulos, V. , et al.	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
		"International Search Report in PCT/US99/18507", (June 15, 2000),7 Pages		
		"International Search Report in PCT/US 99/05853", 5 Pages		
		BOYLE, T P., et al., "Structure of the murine gene encoding apolipoprotein A-I.", <u>Gene</u> , 117(2), (August 15, 1992),243-7		
		DON, J , et al., "Identification and characterization of the regulated pattern of expression of a novel mouse gene, meg1, during the meiotic cell cycle", <u>Cell Growth Differ.</u> , 3(8), (August 1992),495-505		
		DON, J. , "M. musculus mRNA meg1", <u>Database EMBL [Online] AC X64455</u> , (02/21/1992),2 Pages		
		EVER, L , et al., "Two alternatively spliced Meig1 messenger RNA species are differentially expressed in the somatic and in the germ-cell compartments of the testis", <u>Cell Growth Differ.</u> , 10(1), (January 1999),19-26		
		FARGES, R , et al., "Site-directed mutagenesis of the peripheral benzodiazepine receptor: identification of amino acids implicated in the binding site of Ro5-4864", <u>Mol. Pharmacol.</u> , 46(6), (December 1994),1160-7		
		GALIEGUE, S. , et al., "Cloning and Characterization of PRAX-1 - A New Protein that Specifically Interacts with the Peripheral Benzodiazepine Receptor", <u>The Journal of Biological Chemistry</u> , 274(5), (Jan. 29, 1999),2938-2952		
		GLENNEY, J R., et al., "The sequence of human caveolin reveals identity with VIP21, a component of transport vesicles.", <u>FEBS Letters</u> , 314(1), (December 7, 1992),45-48		
		HARDWICK, M. , et al., "Abstract #1569 The Peripheral-type Benzodiazepine Receptor in Human Breast Cancer", <u>Proceedings of the American Association for Cancer Research</u> , 38, (Apr., 1997),233		

EXAMINER

DATE CONSIDERED






Substitute Form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)	<i>Complete if Known</i>	
	<b>Application Number</b>	09/047,652
	<b>Filing Date</b>	March 25, 1998
	<b>First Named Inventor</b>	Papadopoulos, Vassilios
	<b>Group Art Unit</b>	1642
	<b>Examiner Name</b>	Davis, Minh-Tam
Sheet 2 of 3		Attorney Docket No: 1941.016US1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		HARDWICK, M. , et al., "Peripheral-Type Benzodiazepine Receptor (PBR) in Human Breast Cancer: Correlation of Breast Cancer Cell Aggressive Phenotype with PBR Expression, Nuclear Localization, and PBR-mediated Cell Proliferation and Nuclear Transport of Cholesterol", <u>Cancer Research</u> , 59(4), (1999),831-842	
		KOZIKOWSKI, A. P., et al., "Synthesis and Biology of a 7-Nitro-2,1,3-benzoxadiazol-4-yl Derivative of 2-Phenylindole-3-acetamide: A Fluorescent Probe for the Peripheral-Type Benzodiazepine Receptor", <u>Journal of Medicinal Chemistry</u> , 40(16), (1997),2435-2439	
		KRUEGER, K. E., et al., "Peripheral-type Benzodiazepine Receptors Mediate Translocation of Cholesterol from Outer to Inner Mitochondrial Membranes in Adrenocortical Cells", <u>The Journal of Biological Chemistry</u> , 265(25), (1990),15015-15022	
		LI, HUA , et al., "Identification, Localization, and Function in Steroidogenesis of PAP7: A Peripheral-Type Benzodiazepine Receptor- and PKA (RI?N)-Associated Protein", <u>Molecular Endocrinology</u> 15(12), (2001),2211-2228	
		LI, H. , et al., "M. musculus peripheral benzodiazepine receptor associated protein", <u>Database EMBL [Online] AC AF022770</u> , (October 1, 1997),1 page	
		LI, H. , et al., "Peripheral-type benzodiazepine receptor function in cholesterol transport. Identification of a putative cholesterol recognition/interaction amino acid sequence and consensus pattern", <u>Endocrinology</u> , 139(12), (1999),4991-4997	
		MARRA, M. , et al., "mo98e12.rl Stratagene mouse testis (#937308) Mus musculus cDNA clone", <u>Database EMBL [Online] AC AA174581</u> , (Dec. 31, 1996),2 Pages	
		MIETTINEN, H. , et al., "Expression of peripheral-type benzodiazepine receptor and diazepam binding inhibitor in human astrocytomas: relationship to cell proliferation", <u>Cancer Research</u> , 55(12), (June 15, 1995),2691-5	
		PAPADOPOULOS, V. , et al., "CHOLESTEROL RECOGNITION SEQUENCE", <u>US Patent Application Ser. No. 09/623,922</u> , filed September 11, 2000 (1941.017US1).	
		PAPADOPOULOS, V. , et al., "PERIPHERAL-TYPE BENZODIAZEPINE RECEPTOR: A TOOL FOR DETECTION, DIAGNOSIS, PROGNOSIS, AND TREATMENT OF CANCER", <u>US Patent Application Ser. No. 09/646,932</u> , filed September 25, 2000 (1941.016US2).	
		PAPADOPOULOS, V , "Structure and function of the peripheral-type benzodiazepine receptor in steroidogenic cells", <u>Proceedings of the Society for Experimental Biology &amp; Medicine</u> , 217(2), (February 2, 1998),130-142	
		PAWLIKOWSKI, M. , et al., "Inhibition of Cell Proliferation of Human Gliomas by Benzodiazepines in vitro", <u>Acta Neurol Scand.</u> , 77, (1988),231-233	

EXAMINER

DATE CONSIDERED



Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)	Complete if Known	
	Application Number	09/047,652
	Filing Date	March 25, 1998
	First Named Inventor	Papadopoulos, Vassilios
	Group Art Unit	1642
	Examiner Name	Davis, Minh-Tam
Sheet 3 of 3		Attorney Docket No: 1941.016US1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		PIKULEVA, IRINA A., et al., "Active-site topology of bovine cholestrol side-chain cleavage cytochrome P450 (P450scc) and evidence for interaction of tyrosine 94 with the side chain of cholesterol", <u>Archives of Biochemistry and Biophysics</u> , 322(1), (September 10, 1995),189-97	
		RIOND, J. , et al., "Molecular cloning and chromosomal localization of a human peripheral-type benzodiazepine receptor", <u>European Journal of Biochemistry</u> , 195(2), (Jan., 1991),305-311	
		SAMBROOK, J. , et al., "Molecular Cloning - a Laboratory Manual", 2d Edition, Cold Spring Laboratory Press, (1989),9.47-9.62	
		SHER, I , et al., "Mutations uncouple human fibroblast growth factor (FGF)-7 biological activity and receptor binding and support broad specificity in the secondary receptor binding site of FGFs.", <u>Journal of Biological Chemistry</u> , 274(49), (December 3, 1999),35016-35022	
		SU, P , et al., "A cDNA encoding a rat mitochondrial cytochrome P450 catalyzing both the 26-hydroxylation of vitamin D3: gonadotropic regulation of the cognate mRNA in ovaries", <u>DNA and Cell Biology</u> 9(9), (November 1990),657-67	
		YAKOVLEV, et al., "GenBank TM Database Entry", <u>Accession No. U12421</u> , (1995),	

EXAMINER

DATE CONSIDERED